Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/222390
Title: | The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential |
Author: | Verdú Bou, Miriam Baptista, Maria Joao Lima Ribeiro, Marcelo Méndez López, Aleix Profitós Pelejà, Núria Frontzek, Fabian Roué, Gaël Mate, José L. Pellicer, Mireia Abrisqueta, Pau Castellví, Josep Bastos Oreiro, Mariana Menárguez, Javier Alcoceba, Miguel González Barca, Eva Climent, Fina Salar, Antonio Sancho, Juan Manuel Staiger, Annette M. Ott, German Anagnostopoulos, Ioannis Esteller, Manel Lenz, Georg Tapia, Gustavo Navarro, José Tomás |
Keywords: | Cèl·lules B Proteïnes supressores de tumors B cells Tumor suppressor protein |
Issue Date: | 9-Apr-2025 |
Publisher: | American Society of Hematology |
Abstract: | Plasmablastic lymphoma (PBL) is an uncommon and aggressive B-cell lymphoma with a poor prognosis. Some studies have described genetic alterations in PBL, but its transcriptome has been scarcely studied, and molecular mechanisms driving lymphomagenesis remain poorly understood. Our goal was to delineate transcriptomic profiles to identify potential biomarkers for novel targeted therapy in PBL. RNA sequencing uncovered an enrichment of cell cycle-related genes, including MYC and E2F targets, and genes involved in G2/M checkpoint in PBL. Microarray analyses discovered 2 microRNA expression signatures depending on the presence of MYC translocation. Interestingly, miR-150-5p was downregulated, whereas E2F3 and BIRC5 (survivin), a cell cycle activator and an antiapoptotic regulator, respectively, were upregulated. Increasing miR-150-5p in PBL-1 cells induced G1 cell cycle arrest, suppressed proliferation by transcriptionally repressing E2F3, and promoted apoptosis by the downregulation of BIRC5. Interestingly, the miR-150-5p tumor suppressor activity was diminished in E2F3-knockdown cells. The combined inhibition of E2F3 and survivin attenuated lymphomagenesis in PBL cells and suppressed tumor growth in a chorioallantoic membrane-derived xenograft model of PBL. Overall, our study highlights the pivotal role of the miR-150-5p/E2F3/survivin axis in boosting PBL lymphomagenesis and unveils new therapeutic targets for this lymphoma. |
Note: | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2025016180 |
It is part of: | Blood Advances, 2025, vol. 9, num. 12, p. 2953-2967 |
URI: | https://hdl.handle.net/2445/222390 |
Related resource: | https://doi.org/10.1182/bloodadvances.2025016180 |
ISSN: | 2473-9537 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
blooda_adv-2025-016180-main.pdf | 4.2 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License